The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Epacadostat plus pembrolizumab in patients with advanced urothelial carcinoma: Preliminary phase I/II results of ECHO-202/KEYNOTE-037.
 
David C. Smith
Research Funding - Agensys (Inst); Atterocor (Inst); Bayer (Inst); Boston Biomedical (Inst); Bristol-Myers Squibb/Medarex (Inst); Celgene (Inst); ESSA (Inst); Exelixis (Inst); Genentech (Inst); ImClone Systems (Inst); Incyte (Inst); Lilly (Inst); MedImmune (Inst); Medivation/Astellas (Inst); Millennium (Inst); Novartis (Inst); Oncogenex (Inst); OncoMed (Inst); Regeneron (Inst); Seagen (Inst); Takeda (Inst); Tekmira (Inst); Teva (Inst)
 
Thomas Gajewski
Consulting or Advisory Role - Abbvie; Aduro Biotech; Amgen; Bayer; FORMA Therapeutics; Jounce Therapeutics; Merck; Roche/Genentech
Research Funding - Bristol-Myers Squibb (Inst); Incyte (Inst); Merck (Inst); Ono Pharmaceutical (Inst); Roche/Genentech (Inst); Seagen (Inst)
Patents, Royalties, Other Intellectual Property - Licensing to Evelo (Inst)
 
Omid Hamid
Consulting or Advisory Role - Amgen; Bristol-Myers Squibb; Merck; Novartis; Roche
Speakers' Bureau - Amgen; Bristol-Myers Squibb; Genentech; Novartis
Research Funding - AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Celldex (Inst); Genentech (Inst); Immunocore (Inst); Incyte (Inst); MedImmune (Inst); Merck (Inst); Merck Serono (Inst); Novartis (Inst); Pfizer (Inst); Rinat (Inst); Roche (Inst)
 
Jeffrey S. Wasser
Stock and Other Ownership Interests - Biogen; Bristol-Myers Squibb; Johnson & Johnson; Lilly; Merck (I); Pfizer (I)
Consulting or Advisory Role - Amgen; Novartis
Research Funding - Amgen; Incyte; Pfizer
Travel, Accommodations, Expenses - Amgen
 
Anthony J. Olszanski
Consulting or Advisory Role - Bristol-Myers Squibb; G1 Therapeutics; Kyowa Hakko Kirin; Merck; Takeda
Research Funding - Advaxis (Inst); Amgen (Inst); Bristol-Myers Squibb (Inst); EMD Serono (Inst); Ignyta (Inst); Immunocore (Inst); Incyte (Inst); Kura Oncology (Inst); Kyowa Hakko Kirin (Inst); Lilly (Inst); Mirati Therapeutics (Inst); Novartis (Inst); Pfizer (Inst); Takeda (Inst)
Travel, Accommodations, Expenses - Churchill Pharmaceuticals; G1 Therapeutics; Kyowa Hakko Kirin; Takeda
 
Sandip P. Patel
Consulting or Advisory Role - Lilly; Novartis
Speakers' Bureau - Boehringer Ingelheim; Merck
Research Funding - Bristol-Myers Squibb; Incyte; Lilly; MedImmune; Pfizer; Roche/Genentech; Xcovery
 
Ronac Mamtani
Consulting or Advisory Role - Takeda
 
Emmett V. Schmidt
Employment - Merck
Stock and Other Ownership Interests - Merck
 
Yufan Zhao
Employment - Amgen (I); Incyte
Stock and Other Ownership Interests - Amgen (I); Incyte
Travel, Accommodations, Expenses - Amgen (I); Incyte
 
Janet E. Maleski
Employment - Incyte
Stock and Other Ownership Interests - Incyte
 
Tara C. Gangadhar
Honoraria - Medscape
Research Funding - Bristol-Myers Squibb (Inst); Incyte (Inst); Merck (Inst)